Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Global Polio Vaccine Switch in April 2016

by Global Biodefense Staff
November 2, 2015
Global Polio Vaccine Switch

A landmark decision made in Geneva last month will pave the way for a worldwide switch from trivalent to bivalent oral polio vaccine, beginning in April 2016.

The Strategic Advisory Group of Experts on Immunization (SAGE), part of the World Health Organization, recently confirmed the globally coordinated withdrawal next spring of the type 2 component in the oral poliovirus vaccine (OPV).

SAGE’s landmark decision follows the endorsement by the World Health Assembly (WHA) in May 2015, when Ministers of Health from 194 member states adopted a resolution on the global effort to eradicate polio.

The Group encouraged all countries and the partners of the Global Polio Eradication Initiative (GPEI) to begin to intensify their preparatory efforts to switch from trivalent oral polio vaccine (tOPV) to bivalent OPV (bOPV), which is scheduled to occur from 17 April to 1 May 2016.

SAGE concluded that significant progress had been made since its last meeting in April 2015, with no cases in Africa since August and over a year having passed since the last case in the Middle East was seen, strengthened surveillance and more children being reached with vaccines in key areas of Pakistan and Afghanistan.

Withdrawing OPV type 2 is a crucial part of the polio endgame strategy, in order to eliminate the very rare cases of vaccine associated paralytic polio (VAPP) or circulating vaccine derived polioviruses (cVDPVs).

The type 2 component of OPV accounts for 40% of VAPP cases, and upwards of 90% of cVDPV cases. By contrast, wild poliovirus type 2 has not been detected anywhere since 1999 and the Global Commission for the Certification of Poliomyelitis Eradication (GCC) declared this strain globally eradicated at its meeting in September 2015.

The withdrawal of type 2 OPV will ultimately eliminate the risk of emergence of new cVDPV2s in the future, and will also prevent upwards of 200 cases of VAPP that currently occur each year as a result of the type 2 component in trivalent OPV.

Learn more about these efforts at the Global Polio Eradication Initiative.

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Liverpool Synthetic Biology Lab Backed By 2M Award
Policy + Initiatives

Political Interference: White House Launches Framework to Protect Scientific Integrity

January 13, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC